{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:44:16Z","timestamp":1792799056971,"version":"4.5.0"},"reference-count":41,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NCI","award":["K08CA252174"],"award-info":[{"award-number":["K08CA252174"]}]},{"name":"IMS and Paula and Rodger Riney Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/050a7g229","id-type":"ROR","asserted-by":"crossref"}]},{"name":"DOD","award":["CA210827"],"award-info":[{"award-number":["CA210827"]}]},{"name":"BZKF","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Dietmar Hopp Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"DFG","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100009379","name":"IZKF W\u00fcrzburg","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,9,8]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed\/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS) and immune effector cell-associated hematotoxicity (ICAHT), predisposing for life-threatening infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective observational study examined a total of 129 patients with RRMM who had received idecabtagene vicleucel (ide-cel) at two major myeloma centers in Germany and one center in the USA to assess the Endothelial Activation and Stress Index (EASIX) as a risk marker for an unfavorable clinical course and outcome after CAR T-cell therapy. EASIX is calculated by lactate dehydrogenase (U\/L) \u00d7 creatinine (mg\/dL) \/ platelets (10\n                      <jats:sup>9<\/jats:sup>\n                      cells\/L) and was determined before lymphodepletion (baseline) and at the day of CAR T-cell infusion (day 0). The analysis was extended to EASIX derivatives and the CAR-HEMATOTOX score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An elevated baseline EASIX (&gt;median) was identified as a risk marker for severe late ICAHT, manifesting with an impaired hematopoietic reconstitution and pronounced cytopenias during the late post-CAR-T period. Patients with high EASIX levels (&gt;upper quartile) were particularly at risk, as evidenced by an increased rate of an aplastic phenotype of neutrophil recovery, severe late-onset infections and ICANS. Finally, we found associations between baseline EASIX and an inferior progression-free and overall survival. Moreover, the EASIX at day 0 also demonstrated potential to serve as a risk marker for post-CAR-T complications and adverse outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, EASIX aids in risk stratification at clinically relevant time points prior to CAR T-cell therapy with ide-cel. Increased EASIX levels might help clinicians to identify vulnerable patients to adapt peri-CAR-T management at an early stage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-009220","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T23:10:20Z","timestamp":1728342620000},"page":"e009220","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9682-2601","authenticated-orcid":false,"given":"Jan H","family":"Frenking","sequence":"first","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"Clinical Cooperation Unit Molecular Hematology\/Oncology, German Cancer Research Center, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Wagner","sequence":"additional","affiliation":[{"name":"Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, German Cancer Research Center, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kauer","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"Molecular Medicine Partnership Unit, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco J","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"Eli and Edythe L Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hajiyianni","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Breitkreutz","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Costello","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"Clinical Cooperation Unit Molecular Hematology\/Oncology, German Cancer Research Center, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"National Center for Tumor Diseases, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luft","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"National Center for Tumor Diseases, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Topp","sequence":"additional","affiliation":[{"name":"Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Raab","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg, Baden-W\u00fcrttemberg, Germany"},{"name":"Clinical Cooperation Unit Molecular Hematology\/Oncology, German Cancer Research Center, Heidelberg, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"2025100302344248000_12.10.e009220.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100302344248000_12.10.e009220.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2025100302344248000_12.10.e009220.3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100302344248000_12.10.e009220.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100302344248000_12.10.e009220.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"2025100302344248000_12.10.e009220.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"2025100302344248000_12.10.e009220.7","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"key":"2025100302344248000_12.10.e009220.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100302344248000_12.10.e009220.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01756-w"},{"key":"2025100302344248000_12.10.e009220.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025100302344248000_12.10.e009220.11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am J Hematol"},{"key":"2025100302344248000_12.10.e009220.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study","volume":"13","author":"Korell","year":"2022","journal-title":"Front Immunol"},{"key":"2025100302344248000_12.10.e009220.13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"key":"2025100302344248000_12.10.e009220.14","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"2025100302344248000_12.10.e009220.15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","article-title":"EASIX and mortality after allogeneic stem cell transplantation","volume":"55","author":"Luft","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025100302344248000_12.10.e009220.16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00134-022-06676-3","article-title":"Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation","volume":"48","author":"Korell","year":"2022","journal-title":"Intensive Care Med"},{"key":"2025100302344248000_12.10.e009220.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0247-z","article-title":"EASIX for prediction of survival in lower-risk myelodysplastic syndromes","volume":"9","author":"Merz","year":"2019","journal-title":"Blood Cancer J"},{"key":"2025100302344248000_12.10.e009220.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07317-y","article-title":"Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma","volume":"20","author":"Song","year":"2020","journal-title":"BMC Cancer"},{"key":"2025100302344248000_12.10.e009220.19","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"2025100302344248000_12.10.e009220.20","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"2025100302344248000_12.10.e009220.21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225443","article-title":"Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities","volume":"15","author":"de Boer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100302344248000_12.10.e009220.22","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179506","article-title":"Easix indices predict CRS and overall survival in adult CAR-T Cell recipients","volume":"142","author":"Gavriilaki","year":"2023","journal-title":"Blood"},{"key":"2025100302344248000_12.10.e009220.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"2025100302344248000_12.10.e009220.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"2025100302344248000_12.10.e009220.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647636"},{"key":"2025100302344248000_12.10.e009220.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025100302344248000_12.10.e009220.27","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100302344248000_12.10.e009220.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0068-5","article-title":"A systematic classification of death causes in multiple myeloma","volume":"8","author":"Mai","year":"2018","journal-title":"Blood Cancer J"},{"key":"2025100302344248000_12.10.e009220.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074819","article-title":"Evaluation of clinical prediction models (part 1): from development to external validation","volume":"384","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"2025100302344248000_12.10.e009220.30","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025100302344248000_12.10.e009220.31","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"key":"2025100302344248000_12.10.e009220.32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","article-title":"High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents","volume":"85","author":"Terpos","year":"2010","journal-title":"Eur J Haematol"},{"key":"2025100302344248000_12.10.e009220.33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.175"},{"key":"2025100302344248000_12.10.e009220.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2021.05.018"},{"key":"2025100302344248000_12.10.e009220.35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature New Biol"},{"key":"2025100302344248000_12.10.e009220.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.02.001"},{"key":"2025100302344248000_12.10.e009220.37","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed\/Refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"key":"2025100302344248000_12.10.e009220.38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100302344248000_12.10.e009220.39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0822"},{"key":"2025100302344248000_12.10.e009220.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100302344248000_12.10.e009220.41","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:34:51Z","timestamp":1759484091000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,7]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/jitc-2024-009220"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009220","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}